(ICAD) icad - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US44934S2068
ICAD: Cancer, Detection, Therapy, Solutions, Breast, Imaging, Software
iCAD, Inc. (NASDAQ:ICAD) is a leading provider of innovative cancer detection and therapy solutions, operating through two core segments: Detection and Therapy. The company specializes in advanced imaging and radiation therapy solutions, focusing on improving patient outcomes in oncology. Its product portfolio includes ProFound AI, a cutting-edge solution for digital breast tomosynthesis and 2D mammography; PowerLook, a tool for breast density assessment; and ProFound Risk, which offers personalized breast cancer risk analysis. These solutions leverage AI and machine learning to enhance diagnostic accuracy and patient care.
Founded in 1984 under the name Howtek, Inc., the company rebranded as iCAD, Inc. in 2002 to reflect its expanded focus on medical imaging and cancer detection. Headquartered in Nashua, New Hampshire, iCAD has established itself as a key player in the medical technology sector, particularly in the areas of breast health and radiation oncology. Its commitment to innovation has positioned it at the forefront of AI-driven healthcare solutions.
From a technical standpoint, ICADs stock has shown volatility, with a 20-day average volume of 447,048 shares. The stock is currently trading at $2.25, below its 20-day SMA of $2.94 and 50-day SMA of $2.54. The 200-day SMA stands at $1.81, indicating potential long-term upside. The ATR of $0.30 reflects moderate price fluctuations. On the fundamental side, the company has a market cap of $66.94 million, with a price-to-book ratio of 2.28 and a price-to-sales ratio of 3.53. The negative return on equity (-11.58%) highlights ongoing profitability challenges.
3-Month Forecast: Based onAdditional Sources for ICAD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ICAD Stock Overview
Market Cap in USD | 58m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 1986-12-03 |
ICAD Stock Ratings
Growth 5y | -50.8% |
Fundamental | -41.9% |
Dividend | 0.0% |
Rel. Strength Industry | 41 |
Analysts | 4.75/5 |
Fair Price Momentum | 1.84 USD |
Fair Price DCF | - |
ICAD Dividends
No Dividends PaidICAD Growth Ratios
Growth Correlation 3m | 61.6% |
Growth Correlation 12m | 69.1% |
Growth Correlation 5y | -82.6% |
CAGR 5y | -21.95% |
CAGR/Max DD 5y | -0.23 |
Sharpe Ratio 12m | -0.05 |
Alpha | 19.47 |
Beta | 2.86 |
Volatility | 78.40% |
Current Volume | 216.6k |
Average Volume 20d | 385.7k |
As of March 16, 2025, the stock is trading at USD 2.29 with a total of 216,583 shares traded.
Over the past week, the price has changed by +2.23%, over one month by -31.02%, over three months by +26.52% and over the past year by +42.24%.
Probably not. Based on ValueRay Fundamental Analyses, icad (NASDAQ:ICAD) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -41.89 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ICAD as of March 2025 is 1.84. This means that ICAD is currently overvalued and has a potential downside of -19.65%.
icad has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy ICAD.
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ICAD icad will be worth about 2.2 in March 2026. The stock is currently trading at 2.29. This means that the stock has a potential downside of -4.37%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 4.5 | 96.5% |
Analysts Target Price | 4.4 | 91.3% |
ValueRay Target Price | 2.2 | -4.4% |